ClinicalTrials.gg
RecruitingNCT06906341Updated Nov 16, 2026

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

A Phase 2 interventional study of Relacorilant 150 mg once daily (QD) and Nab-paclitaxel 80 mg/m^2 in Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Neoplasms, sponsored by Corcept Therapeutics. Recruiting at 53 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Planned enrollment
19th of 106
270 · median 52
Started
2025
with 8 others
Phase 2
66 of 106
11 open now
Primary completion
2027-12
later than 17 of 31 live
Registered
94th of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 19th largest by planned enrollment, is one of 9 that started in 2025, is one of 66 in phase 2, reaches primary completion later than 17 of the 31 other live ones, and was the 94th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Read the detailed description

This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.

For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m\^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms
  • Endometrial Cancer

Keywords

  • Genital Neoplasms, Female
  • Neoplasms by Site
  • Fallopian Tube Diseases
  • Ovarian Diseases
  • Neoplasms
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Paclitaxel
  • Albumin-Bound Paclitaxel
  • Ovarian
  • Peritoneal or Advanced Fallopian Tube Cancer
  • High Grade
  • Platinum Resistant
  • Relacorilant
  • Bella
  • Nab-paclitaxel
  • Bevacizumab
  • Endometrial Neoplasm
  • Endometrial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Arms A and B

  • Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
  • Arm A Only: Platinum-resistant disease
  • Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
  • of ≥3 months
  • (ECOG) performance status 0 or 1
  • Able to swallow and retain oral medication
  • 1 to 3 lines of prior systemic anticancer therapy
  • Adequate organ function
  • Negative pregnancy test for patients of

Arm C

  • Stage III or IV, recurrent, or endometrial cancer
  • Life expectancy of ≥3 months
  • ECOG performance status of 0 or 1
  • Able to swallow and retain oral medication
  • Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
  • 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
  • Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
  • Adequate organ function
  • Negative pregnancy test for patients of childbearing potential

Exclusion criteria

Exclusion Criteria:

Arm A and B

  • Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • Untreated or symptomatic central nervous system
  • History of other within 3 years prior to enrollment
  • Has received a within 30 days prior to the study start date

Arm C

  • Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with corticosteroids
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • History of other malignancy within 3 years prior to enrollment
  • Has received a live vaccine within 30 days prior to the study start date
  • Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab

    In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab.

    Drug: Relacorilant 150 mg once daily (QD) · Drug: Nab-paclitaxel 80 mg/m^2 · Drug: Bevacizumab 10 mg/kg

  • Experimental
    Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab

    In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab.

    Drug: Relacorilant 150 mg once daily (QD) · Drug: Nab-paclitaxel 80 mg/m^2 · Drug: Bevacizumab 10 mg/kg

  • Experimental
    Arm C: Relacorilant in Combination with Nab-Paclitaxel

    In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel.

    Drug: Relacorilant 150 mg once daily (QD) · Drug: Nab-paclitaxel 80 mg/m^2

Interventions

  • Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

    Also known as: CORT125134

  • DrugNab-paclitaxel 80 mg/m^2

    Drug page: Albumin-Bound Paclitaxel

    Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

  • DrugBevacizumab 10 mg/kg

    Drug page: Bevacizumab

    Bevacizumab is administered as IV infusion on Days 1 and 15.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.

    Time frame: Date of first dose until PD or death, up to 18 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1.

    Time frame: Date of first dose until PD or death, up to 18 months

  2. Best Overall Response Rate (BOR)

    To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death.

    Time frame: Date of first dose until PD or death, up to 18 months

  3. Duration of Response (DOR)

    To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first.

    Time frame: Time of first objective response until PD or death, up to 18 months

  4. Clinical Benefit Rate (CBR)

    To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1.

    Time frame: Week 24

  5. Overall Survival (OS)

    To evaluate the probability of OS survival at 6, 12, and 18 months.

    Time frame: Date of first dose up to 6, 12, and 18 months

  6. Number of patients with one or more adverse events

    Time frame: Date of first dose up to 30 days after last dose

  7. Area under the plasma concentration-time curve (AUC) of relacorilant

    To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

    Time frame: On Cycle 1 Day 8 (each cycle is 28 days)

  8. Maximum plasma concentration (Cmax) of relacorilant

    To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

    Time frame: On Cycle1 Day 8 (each cycle is 28 days)

  9. Trough plasma concentrations (Cmin) of relacorilant

    To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

    Time frame: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)

07

Study locations

53 of 53 sites recruiting
  • 004
    Birmingham, Alabama 35233, United States
    Recruiting
  • 150
    Palo Alto, California 94304, United States
    Recruiting
  • 278
    San Francisco, California 94109, United States
    Recruiting
  • 014
    San Francisco, California 94143, United States
    Recruiting
  • 032
    Aurora, Colorado 80045, United States
    Recruiting
  • 544
    Fort Myers, Florida 33901, United States
    Recruiting
  • 335
    Miami Beach, Florida 33140, United States
    Recruiting
  • 543
    West Palm Beach, Florida 33041, United States
    Recruiting
  • 001
    Chicago, Illinois 60637, United States
    Recruiting
  • 518
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • 334
    Kansas City, Missouri 64132, United States
    Recruiting
  • 521
    St Louis, Missouri 63110, United States
    Recruiting
  • 292
    Albuquerque, New Mexico 97102, United States
    Recruiting
  • 304
    Centerville, Ohio 45459, United States
    Recruiting
  • 517
    Eugene, Oregon 97401, United States
    Recruiting
  • 127
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • 522
    Fairfax, Virginia 22031, United States
    Recruiting
  • 300
    Norfolk, Virginia 23502, United States
    Recruiting
  • 121
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • 328
    Aalst, Belgium 9300, Belgium
    Recruiting
  • 109
    Brussels, 1200, Belgium
    Recruiting
  • 326
    Charleroi, 6000, Belgium
    Recruiting
  • 325
    Hasselt, 3500, Belgium
    Recruiting
  • 108
    Leuven, 3000, Belgium
    Recruiting
  • 306
    Lille, 59000, France
    Recruiting
  • 307
    Nancy, 54100, France
    Recruiting
  • 310
    Nice, 06100, France
    Recruiting
  • 324
    Pierre-Bénite, 69495, France
    Recruiting
  • 323
    Plérin, 22190, France
    Recruiting
  • 308
    Toulouse, 31059, France
    Recruiting
  • 519
    Aachen, 52074, Germany
    Recruiting
  • 255
    Berlin, 10117, Germany
    Recruiting
  • 520
    Kempten, 87439, Germany
    Recruiting
  • 321
    Catania, 95126, Italy
    Recruiting
  • 122
    Milan, 20141, Italy
    Recruiting
  • 516
    Milan, 20159, Italy
    Recruiting
  • 295
    Pavia, 27100, Italy
    Recruiting
  • 124
    Rome, 00168, Italy
    Recruiting
  • 293
    Torino, 10128, Italy
    Recruiting
  • 319
    Treviso, 31100, Italy
    Recruiting
  • 341
    Gdynia, 81-519, Poland
    Recruiting
  • 329
    Siedlce, 08-MO, Poland
    Recruiting
  • 396
    Seoul, Gangnam-gu 06351, South Korea
    Recruiting
  • 397
    Gyeonggi-do, Goyang-si 10408, South Korea
    Recruiting
  • 399
    Seoul, Jongno-gu 03080, South Korea
    Recruiting
  • 523
    Seoul, Seocho-gu 06591, South Korea
    Recruiting
  • 398
    Seoul, Seodaemun-gu 03722, South Korea
    Recruiting
  • 403
    Seoul, Songpa-gu 05505, South Korea
    Recruiting
  • 349
    Badalona, 08916, Spain
    Recruiting
  • 115
    Barcelona, 08035, Spain
    Recruiting
  • 114
    Madrid, 28034, Spain
    Recruiting
  • 558
    Valencia, 46010, Spain
    Recruiting
  • 330
    Valencia, 46026, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 32 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Dec 2027 and completion Dec 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 2, 2025
StartActual
Apr 11, 2025
Primary completionEst.
Dec 2027was Aug 2026
CompletionEst.
Aug 2028was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (3 United States, 1 Belgium)
  • 278 · San Francisco, United States
  • 032 · Aurora, United States
  • 001 · Chicago, United States
  • 109 · Brussels, Belgium
Nov 16, 2026
Primary completion
Aug 2026→Dec 2027
Nov 16, 2026
Study completion
Dec 2026→Aug 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    4 sites added
    Show 4 added (3 United States, 1 Belgium)
    • 278 · San Francisco, United States
    • 032 · Aurora, United States
    • 001 · Chicago, United States
    • 109 · Brussels, Belgium
    Primary completion Aug 2026→Dec 2027
    Study completion Dec 2026→Aug 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06906341
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Apr 11, 2025
Primary completion
Dec 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Corcept Therapeutics
Contact
corceptstudy557@corcept.com
650-414-2314
Danny Nguyen, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion